Y-mAbs Therapeutics, Inc. (YMAB)
Stock Price:
$42.30 USD
-0.97 (-2.24%)
Updated Oct 28, 2020 4:00 PM EDT - Market closed
Key Info
| Market Cap |
1.69B |
| Revenue (ttm) |
n/a |
| Net Income (ttm) |
-113.63M |
| Shares Out |
40.01M |
| EPS (ttm) |
-2.99 |
| PE Ratio |
n/a |
| Forward PE |
31.35 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Oct 28, 2020 |
| Last Price |
$42.30 |
| Previous Close |
$43.27 |
| Change ($) |
-0.97 |
| Change (%) |
-2.24% |
| Day's Open |
42.38 |
| Day's Range |
41.43 - 43.08 |
| Day's Volume |
141,439 |
| 52-Week Range |
14.16 - 50.49 |
More Stats
| Market Cap |
1.69B |
| Enterprise Value |
1.54B |
| Earnings Date (est) |
Nov 11, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
40.01M |
| Float |
24.63M |
| EPS (basic) |
-2.98 |
| EPS (diluted) |
-2.99 |
| FCF / Share |
-2.43 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
2.92M |
| Short Ratio |
17.42 |
| Short % of Float |
11.86% |
| Beta |
1.35 |
| PE Ratio |
n/a |
| Forward PE |
31.35 |
| P/FCF Ratio |
n/a |
| PS Ratio |
n/a |
| PB Ratio |
10.96 |
| Revenue |
n/a |
| Operating Income |
-115.32M |
| Net Income |
-113.63M |
| Free Cash Flow |
-97.16M |
| Net Cash |
156.09M |
| Net Cash / Share |
3.90 |
| Gross Margin |
n/a |
| Operating Margin |
n/a |
| Profit Margin |
n/a |
| FCF Margin |
n/a |
| ROA |
-49.14% |
| ROE |
-89.34% |
| ROIC |
2,641.00% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Forecasts
Analyst Ratings (9)
| Buy |
8 |
| Overweight |
0 |
| Hold |
1 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$47.62*
(12.58% upside)
Low
42.0
Current: $42.30
High
52.0
Target: 47.62
*Average 12-month price target from 8 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 |
|---|
| Revenue | - | - | - | - |
| Operating Income | -83.00 | -43.23 | -19.24 | -17.04 |
| Net Income | -81.03 | -43.27 | -19.16 | -17.06 |
| Shares Outstanding | 35.18 | 28.77 | 19.40 | 14.09 |
| Earnings Per Share | -2.30 | -1.50 | -0.99 | -1.21 |
| Operating Cash Flow | -73.50 | -41.23 | -15.87 | -11.17 |
| Capital Expenditures | -1.97 | -0.23 | - | - |
| Free Cash Flow | -75.46 | -41.46 | -15.87 | -11.17 |
| Cash & Equivalents | 207 | 148 | 90.52 | 16.90 |
| Total Debt | 2.23 | - | - | - |
| Net Cash / Debt | 205 | 148 | 90.52 | 16.90 |
| Assets | 216 | 152 | 92.13 | 17.26 |
| Liabilities | 17.46 | 11.40 | 9.98 | 5.20 |
| Book Value | 199 | 141 | 82.15 | 12.06 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Y-mAbs Therapeutics, Inc. |
| Country |
United States |
| Employees |
65 |
| CEO |
Claus Juan Møller-San Pedro |
Stock Information
| Ticker Symbol |
YMAB |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: YMAB |
| IPO Date |
September 21, 2018 |
Description
Y-mAbs Therapeutics, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody-based therapeutic products for the treatment cancer in the United States. The company develops naxitamab that is in Phase 2 clinical trial for the treatment of pediatric patients with relapsed steosarcoma or refractory, and high-risk neuroblastoma, as well as other GD2 positive tumors; and GD2-GD3 Vaccine which is in Phase 2 clinical trial for the treatment of high-risk neuroblastoma. It is developing omburtamab that is in Phase 2 clinical trial for the treatment of desmoplastic small round cell tumors; in Phase 1 clinical trial for the treatment of diffuse intrinsic pontine glioma, as well as for the treatment of pediatric patients with central nervous system and leptomeningeal metastases; The company also engages in the development of huB7-H3 product candidate for the treatment of B7-H3 positive adult solid tumors; and pre clinical development of huCD33 BsAb product candidate for the treatment of huCD33 positive hermatological cancers. The company has a license and research collaboration agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize antibody constructs based on the SADA-BiDE pre-targeted radioimmunotherapy platform. Y-mAbs Therapeutics, Inc. was founded in 2015 and is headquartered in New York, New York.